Milestone Pharmaceuticals Inc. - 8-K Filing
Milestone Pharmaceuticals reports Q3 2026 CARDAMYST revenue of $1.0 million and announces cost-efficiency measures to reduce operating expenses by 30%. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $MIST
Read the full article at SEC EDGAR
Part of the story Stark Novus Financial Inc. - 8-K Filing (3 articles)